Zoledronic Acid Patent Expiration
Zoledronic Acid is used for increasing bone mass and treating osteoporosis in postmenopausal women and men. It was first introduced by Novartis Pharmaceuticals Corp
Zoledronic Acid Patents
Given below is the list of patents protecting Zoledronic Acid, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Reclast |
US7932241 (Pediatric) | Pharmaceutical products comprising bisphosphonates | Aug 05, 2028 | Sandoz |
| Reclast | US7932241 | Pharmaceutical products comprising bisphosphonates | Feb 05, 2028 | Sandoz |
| Zometa | US7932241 | Pharmaceutical products comprising bisphosphonates | Feb 05, 2028 | Novartis |
| Zometa |
US8324189 (Pediatric) | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | Nov 29, 2025 | Novartis |
| Zometa | US8324189 | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
May 29, 2025
(Expired) | Novartis |
| Reclast | US8052987 | Method of administering bisphosphonates |
Oct 27, 2023
(Expired) | Sandoz |
| Reclast |
US4939130 (Pediatric) | Substituted alkanediphosphonic acids and pharmaceutical use |
Mar 02, 2013
(Expired) | Sandoz |
| Zometa |
US4939130 (Pediatric) | Substituted alkanediphosphonic acids and pharmaceutical use |
Mar 02, 2013
(Expired) | Novartis |
| Reclast | US4939130 | Substituted alkanediphosphonic acids and pharmaceutical use |
Sep 02, 2012
(Expired) | Sandoz |
| Zometa | US4939130 | Substituted alkanediphosphonic acids and pharmaceutical use |
Sep 02, 2012
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Zoledronic Acid's patents.
Latest Legal Activities on Zoledronic Acid's Patents
Given below is the list recent legal activities going on the following patents of Zoledronic Acid.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 May, 2024 | US8324189 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Apr, 2023 | US8052987(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 May, 2020 | US8324189 |
| Expire Patent Critical
| 03 Jun, 2019 | US7932241 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Apr, 2019 | US8052987(Litigated) |
| Maintenance Fee Reminder Mailed Critical
| 17 Dec, 2018 | US7932241 |
| Recordation of Patent Grant Mailed Critical
| 04 Dec, 2012 | US8324189 |
| Patent Issue Date Used in PTA Calculation Critical
| 04 Dec, 2012 | US8324189 |
| Email Notification Critical
| 15 Nov, 2012 | US8324189 |
| Issue Notification Mailed Critical
| 14 Nov, 2012 | US8324189 |
Zoledronic Acid's Family Patents
